BBIO insider ownership: who sold, why, and what they still hold

What stands out

Three directors sold $11.9M with no disclosed plan: Andrew Lo ($6.3M), Ronald Daniels ($3.9M) and Hannah Valantine ($1.7M). The filings don't state a reason.Andrew Lo: largest such sale, Nov 17, 2025 · Ronald Daniels: largest such sale, Nov 6, 2025 · Hannah Valantine: largest such sale, Nov 12, 2025

A share of stake is shown for 0 of the 10 officers and directors who sold. 16 are left out

Left out: Neil Kumar, Frank McCormick, Charles Homcy, Thomas Trimarchi, Ali Satvat, Andrew Lo, Maricel Apuli, James Momtazee, Douglas Dachille, Fred Hassan, Randal Scott, Andrea Ellis, Ronald Daniels, Jennifer Cook, Hannah Valantine and Eric Aguiar (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Neil Kumar

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$57.2MDisclosed plan

Jennifer Cook

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$21.9MDisclosed plan

Frank McCormick

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$13.3MDisclosed plan

Andrew Lo

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$6.3MNo plan disclosed

Andrea Ellis

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.7MDisclosed plan

All 10 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 17, 2026Neil Kumar sold 10K shares ($691K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Neil Kumar Chief Executive Officer, Director	10,000	$69.08	n/a	n/a	Sep 17, 2026	Sep 21, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

VIKING GLOBAL INVESTORS LP and KKR Genetic Disorder L.P. reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the BridgeBio Pharma, Inc. CEO selling stock?

Yes. Neil Kumar sold 805K shares ($57.2M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are BridgeBio Pharma, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 90% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 10% had no disclosed plan. A trading plan schedules sales in advance.

Are any BridgeBio Pharma, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold10 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Neil Kumar Chief Executive Officer, Director	$57.2M 805K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Jennifer Cook Director	$21.9M 278K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Frank McCormick Director	$13.3M 200K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Andrew Lo Director	$6.3M 96K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Andrea Ellis Director	$5.7M 82K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Hannah Valantine Director	$4.4M 65K shares	Not confirmed share of stake is being verified. Why	61% under a disclosed plan 39% no plan disclosed
Ronald Daniels Director	$3.9M 61K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Thomas Trimarchi President and CFO	$3.0M 44K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Randal Scott Director	$2.1M 30K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Maricel Apuli Chief Accounting Officer	$622K 8.5K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Outside holder, reported separately: VIKING GLOBAL INVESTORS LP (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: KKR Genetic Disorder L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 16 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Neil Kumar

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Neil Kumar are complete.

Chief Executive Officer, Director

n/a

−805K

n/a

Vesting, gifts, unvested awards and holding lines for Neil Kumar

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Neil Kumar are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−167Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
45,140	$28.70	Mar 11, 2034	$1.8M
71,208	$33.75	Mar 18, 2035	$2.6M
40,570	$70.94	Mar 16, 2036	$0

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Frank McCormick

Director

n/a

−200K

n/a

Vesting, gifts, unvested awards and holding lines for Frank McCormick

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Frank McCormick are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
84,814	$11.92	Feb 20, 2033	$4.9M
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Charles Homcy

Director

n/a

Vesting, gifts, unvested awards and holding lines for Charles Homcy

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Charles Homcy are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−788withheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Thomas Trimarchi

President and CFO

n/a

−44K

n/a

Vesting, gifts, unvested awards and holding lines for Thomas Trimarchi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Thomas Trimarchi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−100Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
115,000	$17.00	Jun 25, 2029	$6.0M
16,419	$42.19	Sep 17, 2030	$450K
22,145	$68.87	Feb 9, 2031	$15K
158,127	$40.03	Dec 1, 2031	$4.7M
3,160	$24.87	Aug 5, 2034	$141K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Ali Satvat

Director

n/a

Vesting, gifts, unvested awards and holding lines for Ali Satvat

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ali Satvat are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Andrew Lo

Director

n/a

−96K

n/a

Vesting, gifts, unvested awards and holding lines for Andrew Lo

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Lo are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Maricel Apuli

Chief Accounting Officer

n/a

−8.5K

n/a

Vesting, gifts, unvested awards and holding lines for Maricel Apuli

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Maricel Apuli are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−21Kwithheld by the company for taxes

James Momtazee

Director

n/a

Vesting, gifts, unvested awards and holding lines for James Momtazee

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Momtazee are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Douglas Dachille

Director

n/a

Vesting, gifts, unvested awards and holding lines for Douglas Dachille

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Douglas Dachille are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Fred Hassan

Director

n/a

Vesting, gifts, unvested awards and holding lines for Fred Hassan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Fred Hassan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Randal Scott

Director

n/a

−30K

n/a

Vesting, gifts, unvested awards and holding lines for Randal Scott

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Randal Scott are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
21,501	$16.75	Jun 21, 2033	$1.1M
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Andrea Ellis

Director

n/a

−82K

n/a

Vesting, gifts, unvested awards and holding lines for Andrea Ellis

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrea Ellis are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
17,167	$16.75	Jun 21, 2033	$907K
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Ronald Daniels

Director

n/a

−61K

n/a

Vesting, gifts, unvested awards and holding lines for Ronald Daniels

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ronald Daniels are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
30,523	$34.65	Feb 11, 2030	$1.1M
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Jennifer Cook

Director

n/a

−278K

n/a

Vesting, gifts, unvested awards and holding lines for Jennifer Cook

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jennifer Cook are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Hannah Valantine exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Hannah Valantine

Director

n/a

−65K

n/a

Vesting, gifts, unvested awards and holding lines for Hannah Valantine

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hannah Valantine are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Jennifer Cook exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
93,261	$8.45	Jun 22, 2032	$5.7M
34,334	$16.75	Jun 21, 2033	$1.8M
17,343	$27.36	Jun 20, 2034	$732K
5,617	$41.73	Jun 19, 2035	$156K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Eric Aguiar

Director

n/a

Vesting, gifts, unvested awards and holding lines for Eric Aguiar

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eric Aguiar are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,014	$27.36	Jun 20, 2034	$1.1M
8,425	$41.73	Jun 19, 2035	$235K
5,277	$68.92	Jun 21, 2036	$3K

Estimate: options held × ($69.57 − strike price), using the most recent insider trade price on Form 4 (Sep 17, 2026), not a market close.

Holdings and share of stake for BridgeBio Pharma, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$118M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $118M across 1,669,551 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $106M · 90%

10%

The lighter segment is sales with no plan disclosed in the filing ($11.9M), including tax-related sales outside a plan.

No plan disclosed · $11.9M

Sales with no 10b5-1 plan and no tax reference in the filing. $6.3M of it is Andrew Lo. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Ronald Daniels, Nov 6, 2025

Taxes

288,135 shares ($20.9M) were withheld by the company for taxes, which isn't a market sale.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Neil Kumar Chief Executive Officer, Director	805K	$57.2M	100%	48%	Nov 6, 2025 to Sep 17, 2026
Jennifer Cook Director	278K	$21.9M	100%	19%	Jun 15, 2026 to Jul 9, 2026
Frank McCormick Director	200K	$13.3M	100%	11%	Oct 27, 2025 to Oct 29, 2025
Andrew Lo Director	96K	$6.3M	0%	5%	Nov 17, 2025 to Nov 18, 2025
Andrea Ellis Director	82K	$5.7M	100%	5%	Mar 4, 2026 to Jul 9, 2026
Hannah Valantine Director	65K	$4.4M	61%	4%	Nov 12, 2025 to Jun 23, 2026
Ronald Daniels Director	61K	$3.9M	0%	3%	Nov 6, 2025 to Nov 6, 2025
Thomas Trimarchi President and CFO	44K	$3.0M	100%	3%	Nov 17, 2025 to May 18, 2026
Randal Scott Director	30K	$2.1M	100%	2%	Nov 17, 2025 to May 15, 2026
Maricel Apuli Chief Accounting Officer	8.5K	$622K	100%	0.5%	Dec 8, 2025 to Jul 30, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$13.3M	$13.3M	$0	$0
Nov 2025	$20.4M	$8.5M	$0	$11.9M
Dec 2025	$8.3M	$8.3M	$0	$0
Jan 2026	$6.0M	$6.0M	$0	$0
Feb 2026	$11.4M	$11.4M	$0	$0
Mar 2026	$10.3M	$10.3M	$0	$0
Apr 2026	$6.1M	$6.1M	$0	$0
May 2026	$8.8M	$8.8M	$0	$0
Jun 2026	$14.5M	$14.5M	$0	$0
Jul 2026	$14.8M	$14.8M	$0	$0
Aug 2026	$3.7M	$3.7M	$0	$0
Sep 2026	$691K	$691K	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 2.1x the 5-year average. 10 insiders sold; the average is 5 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	1.67M	10	$118M
Oct 13, 2025 1 year earlier	2.13M	9	$86.8M
Oct 13, 2024 2 years earlier	227K	5	$7.9M
Oct 14, 2023 3 years earlier	1.37M	3	$15.3M
Oct 14, 2022 4 years earlier	12K	1	$150K
Oct 14, 2021 5 years earlier	303K	5	$16.3M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty16 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for BridgeBio Pharma, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology436 filings on record, 62 filed in the 12-month period, and how we read them

All 436 Forms 3, 4 and 5 on record for BridgeBio Pharma, Inc. (SEC CIK 1743881), filed from Jun 27, 2019 to Sep 21, 2026; 62 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages. 12 filings were left out because BridgeBio Pharma, Inc. filed them as an owner of another company's stock.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (8)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Brian Stephenson	Feb 27, 2025	102,464 shares, last reported balance as of Feb 25, 2025
Richard Scheller	Feb 21, 2023	53,822 shares, last reported balance as of Feb 16, 2023
Brent Saunders	Jun 24, 2022	17,600 shares, last reported balance as of Dec 29, 2021
Cameron Turtle	Dec 29, 2020	12,568 shares, last reported balance as of Dec 28, 2020
Michael Henderson	Dec 17, 2020	274,211 shares, last reported balance as of Dec 1, 2020
Uma Sinha	Dec 17, 2020	16,460 shares, last reported balance as of Nov 16, 2020
Yi Yau	Nov 18, 2020	4,586 shares, last reported balance as of Nov 16, 2020
Brian Stolz	Aug 18, 2020	24,615 shares, last reported balance as of Aug 16, 2020

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

BridgeBio Pharma, Inc. insiders sold $118M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the BridgeBio Pharma, Inc. CEO selling stock?

Why are BridgeBio Pharma, Inc. insiders selling?

Are any BridgeBio Pharma, Inc. insiders buying?

The evidence

No plan disclosed · $11.9M

Taxes

Sales by month